Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs.
Each month, we present a journal club in which we choose a study that we believe will be of interest to the cardio-oncology community and discuss it at a virtual journal club with several of our faculty members.
Read more about the study here.
Panelists
Presenter
